Philip Wahl
Research Subjects
Philip Wahl has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Povl Krogsgaard-Larsen
Department of Molecular Pharmacology, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark (P.W., C.A.), 2Department of Pharmacology, Emory University, Atlanta, GA 30322-3090, USA (S.F.T.), 3Department of Molecular Genetics, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark (J.E., J.S.R.) and 4Department of Medicinal Chemistry, The Royal Danish School of Pharmacy, DK-2100 Copenhagen, Denmark (P.K.-L., U.M.)
2 shared publicationsUlf Madsen
Department of Molecular Pharmacology, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark (P.W., C.A.), 2Department of Pharmacology, Emory University, Atlanta, GA 30322-3090, USA (S.F.T.), 3Department of Molecular Genetics, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark (J.E., J.S.R.) and 4Department of Medicinal Chemistry, The Royal Danish School of Pharmacy, DK-2100 Copenhagen, Denmark (P.K.-L., U.M.)
2 shared publicationsArne Schousboe
1 shared publicationCharlotte Anker
Department of Molecular Pharmacology, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark (P.W., C.A.), 2Department of Pharmacology, Emory University, Atlanta, GA 30322-3090, USA (S.F.T.), 3Department of Molecular Genetics, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark (J.E., J.S.R.) and 4Department of Medicinal Chemistry, The Royal Danish School of Pharmacy, DK-2100 Copenhagen, Denmark (P.K.-L., U.M.)
1 shared publicationJan Egebjerg
Department of Molecular Pharmacology, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark (P.W., C.A.), 2Department of Pharmacology, Emory University, Atlanta, GA 30322-3090, USA (S.F.T.), 3Department of Molecular Genetics, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark (J.E., J.S.R.) and 4Department of Medicinal Chemistry, The Royal Danish School of Pharmacy, DK-2100 Copenhagen, Denmark (P.K.-L., U.M.)
1 shared publicationJesper S. Rasmussen
Department of Molecular Pharmacology, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark (P.W., C.A.), 2Department of Pharmacology, Emory University, Atlanta, GA 30322-3090, USA (S.F.T.), 3Department of Molecular Genetics, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark (J.E., J.S.R.) and 4Department of Medicinal Chemistry, The Royal Danish School of Pharmacy, DK-2100 Copenhagen, Denmark (P.K.-L., U.M.)
1 shared publication
Latest Publications
- 1 March 1998
- Published by Elsevier in Molecular Pharmacology
- Vol. 53 (3) , 590-596
Antagonist Properties of a Phosphono Isoxazole Amino Acid at Glutamate R1–4 (R,S)-2-Amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic Acid Receptor Subtypes
The activity of the (R,S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptor antagonist, (R,S)-2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid (ATPO), at recombinant ionotropic glutamate receptors (GluRs) was evaluated using electrophysiological techniques. Responses at homo- or heterooligomeric AMPA-preferring GluRs expressed in human embryonic kidney (HEK) 293 cells (GluR1-flip) or Xenopus laevisoocytes (GluR1–4-flop or GluR1-flop + GluR2) were potently inhibited by ATPO with apparent dissociation constants (Kb values) ranging from 3.9 to 26 μm. A Schild analysis for kainate (KA)-activated GluR1 receptors showed ATPO to have aKB of 8.2 μmand a slope of unity, indicating competitive inhibition. The antagonism by ATPO at GluR1 was of similar magnitude at holding potentials between −100 mV and +20 mV. In contrast, ATPO (X. laevis oocytes. ATPO produced X.laevis oocytes. Thus, ATPO shows a unique pharmacological profile, being an antagonist at GluR1–4 and a weak partial agonist at GluR5 and GluR5/KA2.
- 1 March 1998
- Published by Elsevier in Molecular Pharmacology
- Vol. 53 (3) , 590-596
Antagonist Properties of a Phosphono Isoxazole Amino Acid at Glutamate R1–4 (R,S)-2-Amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic Acid Receptor Subtypes
The activity of the (R,S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptor antagonist, (R,S)-2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid (ATPO), at recombinant ionotropic glutamate receptors (GluRs) was evaluated using electrophysiological techniques. Responses at homo- or heterooligomeric AMPA-preferring GluRs expressed in human embryonic kidney (HEK) 293 cells (GluR1-flip) or Xenopus laevisoocytes (GluR1–4-flop or GluR1-flop + GluR2) were potently inhibited by ATPO with apparent dissociation constants (Kb values) ranging from 3.9 to 26 μm. A Schild analysis for kainate (KA)-activated GluR1 receptors showed ATPO to have aKB of 8.2 μmand a slope of unity, indicating competitive inhibition. The antagonism by ATPO at GluR1 was of similar magnitude at holding potentials between −100 mV and +20 mV. In contrast, ATPO (X. laevis oocytes. ATPO produced X.laevis oocytes. Thus, ATPO shows a unique pharmacological profile, being an antagonist at GluR1–4 and a weak partial agonist at GluR5 and GluR5/KA2.
- 1 July 1996
- Published by Elsevier in European Journal of Pharmacology
- Vol. 308 (2) , 211-218
Different characteristics of AMPA receptor agonists acting at AMPA receptors expressed in Xenopus oocytes
- 1 July 1996
- Published by Elsevier in European Journal of Pharmacology
- Vol. 308 (2) , 211-218
Different characteristics of AMPA receptor agonists acting at AMPA receptors expressed in Xenopus oocytes